Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.

@article{Budde2003PharmacodynamicsOS,
  title={Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.},
  author={Klemens Budde and Robert L Schmouder and Bjorn A P Nashan and Reinhard R Brunkhorst and Peter W L{\"u}cker and Thomas R Mayer and Laurence J Brookman and Jerry R. Nedelman and Andrej Skerjanec and Torsten Boehler and H N Neumayer},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2003},
  volume={3 7},
  pages={846-54}
}
FTY720, a new and potent immunosuppressant, causes in animal models a rapid, reversible reduction of all subsets of peripheral blood lymphocytes, inducing their migration to secondary lymphoid organs. In this human phase I trial, the pharmacodynamics of single oral doses of FTY720 were evaluated. A randomized, double-blind, placebo-controlled, time-lagged study of six different single ascending oral doses of FTY720 ranging from 0.25 to 3.5 mg was conducted in stable renal transplant patients… CONTINUE READING
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…